Augtyro™ (repotrectinib) – New orphan drug approval
November 15, 2023 - Bristol Myers Squibb announced the FDA approval of Augtyro (repotrectinib), for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
Download PDF
